Novel Entactogen NCE Series Enhances the Potential for Improved Treatment of Addiction Toronto, Ontario–(Newsfile Corp. – January 26, 2022) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing and delivering psychedelic therapeutics to treat addiction, announces the filing of a patent application for a new chemical series of…


Previous articlePT287 – Josh Hardman – Psychedelic Stocks, Data Privacy, and Drug Development
Next articlePsyched Wellness Provides Update on Anti-Inflammatory Study with the National Research Council of Canada